C entral body-fat distribution, as assessed by waist-to-hip ratio (WHR), is a heritable and a well-established risk factor for adverse metabolic outcomes [1] [2] [3] [4] [5] [6] . Lower values of WHR are associated with lower risk of cardiometabolic diseases such as type 2 diabetes 7,8 , or differences in bone structure and gluteal muscle mass 9 . These epidemiological associations are consistent with our previously reported genome-wide association study (GWAS) results of 49 loci associated with WHR (after adjusting for body mass index, WHRadjBMI) 10 . Notably, genetic predisposition to higher WHRadjBMI is associated with increased risk of type 2 diabetes and coronary heart disease (CHD), which seems to be causal 9 .
Results
Protein-coding and splice site variation associations. We conducted a two-stage fixed-effects meta-analysis testing additive and recessive models to detect protein-coding genetic variants that influence WHRadjBMI (Methods and Fig. 1 ). Stage 1 included up to 228,985 variants (218,195 low-frequency or rare) in up to 344,369 individuals from 74 studies of European, South and East Asian, African and Hispanic/Latino descent individuals (Supplementary Data 1-3). Stage 2 assessed 70 suggestive (P < 2 × 10 −6 ) stage 1 variants in two cohorts, UK Biobank (UKBB) and deCODE for a total stage 1 and 2 sample size of 476,546 (88% European). Of the 70 variants considered, two common and five low-frequency or rare were not available in stage 2 (Tables 1 and 2 and Supplementary . Variants are considered novel and statistically significant if they were greater than one megabase (Mb) from a previously identified WHRadjBMI SNP [10] [11] [12] [13] [14] [15] [16] and achieve array-wide significance (P < 2 × 10 −7 , stage 1 and 2).
In our primary meta-analysis, including all stage 1 and 2 samples, we identified 48 coding variants (16 novel) across 43 genes, 47 assuming an additive model and one under a recessive model ( Table 1 and Supplementary Figs. 1-4 ). Due to possible heterogeneity, we also performed European-only meta-analysis. Here, four additional coding variants were significant (three novel) assuming an additive model ( Table 1 and Supplementary Figs. [5] [6] [7] [8] . Of these 52 significant variants, 11 were low-frequency or rare and displayed larger effect estimates than many previously reported common variants 10 , including seven novel variants in RAPGEF3, FGFR2, R3HDML, HIST1H1T, PCNXL3, ACVR1C and DARS2. Variants with MAF ≤1% had effect sizes approximately three times greater than those of common variants (MAF ≥5%). Despite large sample size, we cannot rule out the possibility that additional lowfrequency or rare variants with smaller effects exist (see estimated 80% power in Fig. 2 ). However, in the absence of common variants with similarly large effects, our results point to the importance of investigating LF/RVs. Given established sex differences in the genetic underpinnings of WHRadjBMI 10, 11 , we also performed sex-stratified analyses. We detected four additional novel variants that exhibit significant sex-specific effects (P sexhet < 7.14 × 10 −4 , Methods) in UGGT2 and MMP14 for men; and DSTYK and ANGPTL4 for women ( Table 2 and Supplementary Figs. 9-15); including low-frequency or rare in UGGT2 and ANGPTL4 (MAF men = 0.6% and MAF women = 1.9%, respectively). Additionally, 14 variants from the sex-combined meta-analyses displayed significantly stronger effects in women, including the novel, low-frequency ACVR1C variant (rs55920843, MAF = 1.1%). Overall, 19 of the 56 variants (32%) identified across all meta-analyses (48 from all ancestry, 4 from European-only and 4 from sex-stratified analyses) showed significant sex-specific effects on WHRadjBMI: 16 variants with significantly stronger effects in women and three in men ( Fig. 1) .
In summary, we identified 56 array-wide significant coding variants (P < 2.0 × 10 −7 ); 43 common (14 novel) and 13 low-frequency or rare (9 novel) . For the 55 significant variants from the additive model, we examined potential collider bias 17, 18 (Methods, Supplementary Table 1 and Supplementary Note). Overall, 51 of 55 variants were robust to collider bias 17, 18 . Of these, 25 variants were nominally associated with BMI (P BMI < 0.05), yet effect sizes changed little after correction for potential biases (15% change in effect estimate on average). For four of the 55 SNPs (rs141845046, rs1034405, rs3617, rs9469913), attenuation following correction was noted (P corrected > 9 × 10 −4 , 0.05/55), including one novel variant, rs1034405 in C3orf18, demonstrating a possible overestimation of these effects in the current analysis.
Using stage 1 results, we then aggregated LF/RVs across genes and tested their joint effect with SKAT and burden tests 19 ( Supplementary Table 2 and Methods). None of the five genes that reached array-wide significance (P < 2.5 × 10 −6 , 0.05/16,222 genes tested: RAPGEF3, ACVR1C, ANGPTL4, DNAI1 and NOP2) remained significant after conditioning on the most significant single variant.
Conditional analyses. We next implemented conditional analyses to determine (1) the total number of independent signals identified and (2) whether the 33 variants near known GWAS signals (<+/−1 Mb) represent independent novel associations. We used approximate joint conditional analyses to test for independence in Table 3 ) 19 . Only the RSPO3-KIAA0408 locus contains two independent variants 291 kilo bases apart, rs1892172 in RSPO3 (MAF = 46.1%, P conditional = 4.37 × 10 −23 in the combined sexes and P conditional = 2.4 × 10 −20 in women) and rs139745911 in KIAA0408 (MAF = 0.9%, P conditional = 3.68 × 10 −11 in combined sexes and P conditional = 1.46 × 10 −11 in women, Supplementary Table 3 and Fig. 3a ). For the 33 variants within 1 Mb of previously identified WHRadjBMI SNPs, sex-combined conditional analyses identified one coding variant representing a novel independent signal in a known locus (RREB1; stage 1 meta-analysis, rs1334576, MAF = 44%, P conditional = 3.06 × 10 −7 , Supplementary  Table 4 and Fig. 3b ; UKBB analysis, P conditional = 1.24 × 10 −8 , Supplementary Data 7) . In summary, we identified 56 WHRadjBMI-associated coding variants in 41 independent association signals, 24 of which are new or independent of known GWAS-identified tag SNPs (either >+/−1 Mb or array-wide significant following conditional analyses) ( Fig. 1 ). Thus, we identified 15 common and 9 low-frequency or rare novel and independent variants following conditional analyses.
Gene set and pathway enrichment analysis.
To determine whether significant coding variants highlight novel or previously identified biological pathways, we applied two complementary methods, EC-DEPICT (ExomeChip Data-driven Expression-Prioritized Integration for Complex Traits) 20, 21 and PASCAL 22 (Methods). For PASCAL all variants were used, for EC-DEPICT we examined only 361 variants with suggestive significance (P < 5 × 10 −4 ) 10,23 from the all ancestries combined sexes analysis (which after clumping and filtering became 101 lead variants in 101 genes). We separately analyzed variants that exhibited significant sex-specific effects (P sexhet < 5 × 10 −4 ).
The sex-combined analyses identified 49 significantly enriched gene sets (false discovery rate, FDR < 0.05) that grouped into 25 meta-gene sets (Supplementary Note and Supplementary Data 8, 9) . We noted a cluster of meta-gene sets with direct relevance to metabolic aspects of obesity ('enhanced lipolysis' , 'abnormal glucose homeostasis' , 'increased circulating insulin level' and 'decreased susceptibility to diet-induced obesity'); we observed two significant adiponectin-related gene sets in these meta-gene sets. While 16 . e Effect size is based on the s.d. per effect allele f P value for sex heterogeneity, testing for difference between womenspecific and men-specific beta estimates and standard errors, was calculated using EasyStrata: Winkler et al. 11 . Bold P values met significance threshold after Bonferroni correction (P < 7.14E-04; that is, 0.05/70 variants). g rs1334576 in RREB1 is a new signal in a known locus that is independent from the known signal, rs1294410 (see Supplementary Table 4 and Supplementary Data 7); rs139745911 in KIAA0408 is a secondary signal in a known locus (see Supplementary Table 3 ). h Each flag indicates a that a secondary criterion for significance may not be met; G, P > 5 × 10 −8 (GWAS significant); C, Association signal was not robust against collider bias; S variant was not available in stage 2 studies for validation of stage 1 association. . g P value for sex heterogeneity, testing for difference between women-specific and men-specific beta estimates and standard errors, was calculated using EasyStrata: Winkler et al. 11 . h Effect size is based on the s.d. per effect allele i rs139745911 in KIAA0408 is a secondary signal in a known locus (see Supplementary Table 3 ). j Each flag indicates a that a secondary criterion for significance may not be met; G, P > 5 × 10 −8 (GWAS significant); C, Association signal was not robust against collider bias; S, variant was not availabel in stage 2 studies for validation of stage 1 association. these pathway groups had previously been identified in the GWAS DEPICT analysis ( Fig. 4 ), many of the individual gene sets in these meta-gene sets were not significant in the previous GWAS analysis, such as 'insulin resistance, ' 'abnormal white adipose tissue physiology' and 'abnormal fat cell morphology' (Supplementary Data 8, Fig. 4 and Supplementary Fig. 16a ), but represent similar biological underpinnings implied by the shared meta-gene sets. Despite their overlap with the GWAS results, these analyses highlight novel genes that fall outside known GWAS loci and with strong contributions to the substantially enriched gene sets related to adipocyte and insulin biology (for example, MLXIPL, ACVR1C and ITIH5) ( Fig. 4) .
Locus
Also, we conducted pathway analyses after excluding variants from previous WHRadjBMI analyses 10 (Supplemental Note). Seventy-five loci/genes were included in the EC-DEPICT analysis, and we identified 26 substantially enriched gene sets (13 meta-gene sets). Here, all but one gene set, 'lipid particle size' , were related to skeletal biology, probably reflecting an effect on the pelvic skeleton (hip circumference), shared signaling pathways between bone and fat (such as TGF-beta) and shared developmental origin 24 ( Supplementary Data 9 and Supplementary Fig. 16b ). These previously identified GWAS DEPICT significant findings provide a fully independent replication of their biological relevance for WHRadjBMI.
We used PASCAL (Methods) to further distinguish between enrichment based on coding-only variant associations (this study) and regulatory-only variant associations (up to 20 kb upstream of the gene from a previous GIANT study 10 ), finding 116 significantly enriched coding pathways (FDR < 0.05; Supplementary Data 10). Fig. 3 | Regional association plots for known loci with novel coding signals identified by conditional analyses. Point color reflects r 2 calculated from the ARIC dataset. a, There are two independent variants in RSPO3 and KIAA0408, based on results from the stage 1 all ancestry women (N = 180,131 for RSPO3 and 139,056 for KIAA0408). b, We have a variant in RREB1 that is independent of the GWAS variant rs1294410, based on results from the stage 1 all ancestry sex-combined individuals (N = 319,090; GWAS signal tagging variant rs1294421, rs1294410-rs1294421, r 2 =0.85, 1000 Genomes Phase 3 version 5 all ancestries reference set). This scatter plot displays the relationship between MAF and the estimated effect (β) for each significant coding variant in our meta-analyses. All novel WHRadjBMI variants are highlighted in orange, and variants identified only in models that assume recessive inheritance are denoted by diamonds and only in sex-specific analyses by triangles. Eighty percent power was calculated based on the total sample size in the stage 1 and 2 meta-analysis and P = 2 × 10 −7 . Estimated effects are shown in original units (cm cm −1 ) calculated by using effect sizes in s.d. units times SD of WHR in the ARIC study (sexes combined = 0.067, men = 0.052, women = 0.080).
We also compared the coding pathways to those identified in the total previous GWAS effort (using both coding and regulatory variants) identifying a total of 158 gene sets. Forty-two gene sets were enriched in both analyses, and we found high concordance in the -log10 (P values) between ExomeChip and GWAS gene set enrichment (Pearson's r (coding versus regulatory only) = 0.38, P < 10 −300 ; Pearson's r (coding versus coding + regulatory) = 0.51, P < 10 −300 )). Nonetheless, some gene sets were enriched specifically for variants in coding regions (for example, decreased susceptibility to dietinduced obesity, abnormal skeletal morphology) or unique to variants in regulatory regions (for example, transcriptional regulation of white adipocytes) ( Supplementary Fig. 17 ).
The EC-DEPICT and PASCAL results showed a moderate but strongly significant correlation (for EC-DEPICT and the PASCAL max statistic, r = .28, P = 9.8 × 10 −253 ; for EC-DEPICT and the PASCAL sum statistic, r = 0.287, P = 5.42 × 10 −272 ). Common gene sets strongly implicate a role for skeletal biology, glucose homeostasis/insulin signaling and adipocyte biology ( Supplementary Fig. 18 ).
Cross-trait associations.
To assess the clinical relevance of our identified variants with cardiometabolic, anthropometric and reproductive traits, we conducted association lookups from existing ExomeChip studies of 15 traits (Supplementary Data 11 and Supplementary Fig. 19 ) 21, [25] [26] [27] [28] [29] . Variants in STAB1 and PLCB3 displayed the greatest number of significant associations with seven different traits (P < 9.8 × 10 −4 , 0.05/51 variants tested). Also, these two genes cluster together with RSPO3, DNAH10, MNS1, COBLL1, CCDC92 and ITIH3. The WHR-increasing alleles in this cluster exhibit a previously described pattern of increased cardiometabolic risk (for example, increased fasting insulin, two-hour glucose (TwoHGlu)) and triglycerides and decreased high-density lipoprotein cholesterol (HDL)), but also decreased BMI [30] [31] [32] [33] [34] [35] [36] . The impact of central obesity may be causal, as a 1 s.d. increase in genetic risk of central adiposity was previously associated with higher total cholesterol, triglycerides, fasting insulin and TwoHGlu and lower HDL 9 .
We conducted a search in the NHGRI-EBI GWAS Catalog 37,38 to determine whether our variants are in high linkage disequilibrium (R 2 > 0.7) with variants associated with traits or diseases not covered by our cross-trait lookups (Supplementary Data 12). We identified several cardiometabolic traits (adiponectin, CHD and so on), diet/behavioral traits potentially related to obesity (carbohydrate, fat intake and so on), behavioral and neurological traits (schizophrenia, bipolar disorder and so on) and inflammatory or autoimmune diseases (Crohn's Disease, multiple sclerosis and so on).
Given the established correlation between total body-fat percentage and WHR of up to 0.483 [39] [40] [41] , we examined the association of our top exome variants with both total body-fat percentage and truncal fat percentage available in a sub-sample of UKBB (N = 118,160) ( Supplementary Tables 5 and 6 ). Seven of the common novel variants were significantly associated (P < 0.001, 0.05/48 variants examined) with both body-fat percentage and truncal fat percentage in the sexes-combined analysis (COBLL1, UHRF1BP1, WSCD2, CCDC92, IFI30, MPV17L2, IZUMO1) and two with truncal fat percentage in women only (EFCAB12, GDF5). Only rs7607980 in COBLL1 is near a known body-fat percentage GWAS locus (rs6738627; R 2 = 0.1989, distance, 6,751 base pairs, with our tag SNP) 42 . Of the nine SNPs associated with at least one of these two traits, all variants displayed much greater magnitude of effect on truncal fat percentage compared to body-fat percentage ( Supplementary Fig. 20 ).
Previous studies have demonstrated the importance of examining common and LF/RVs in genes with mutations known to cause monogenic diseases 43, 44 . Thus, we assessed enrichment of WHRadjBMI variants in monogenic lipodystrophy and/or insulin resistance genes 43 PALMD  ITGA7  ITIH5  MLXIPL  PEMT  ACVR1C  PCK1  ZWINT  MCM4  CLSPN  ZNF830  HMGXB4  DARS2  EXOC4  CD8A  NSFL1C  ERI1  TRPM2  RBM19  MTMR6  DR1  AKAP8  HELQ  SETD3  MNS1  THADA  XPO7  FASTKD3  OBFC1  ZNF717  DNAH12  FCAMR  NUCB2  LRRC36  TLR10  UNC13B  AIM1L  CHRNB4  COPG2  MFSD6  MPV17L2  MUC4  AGGF1  ETAA1  SHC2  HERC3  NAALAD2  COL4A6  RASSF9  ADAMTSL1  KRT75  FAM160A1  MAML2  PLCE1  EPHA2  LGR6  ADAMTS17  R3HDML  VPS11  C19orf53  HIST1H1T  DCD  PTPRT  SGSM2  PHF20L1  VSX1  CENPQ  NUDT6  CDK13  POMT1  CRTC3  DAGLB  GRSF1  MGAT5B  WDR25  PSME4  UHRF1BP1  LRP1B  L3MBTL3  KAT6B  JMJD1C  TET2  HINT3  PPP2R3A   F A M3B   RFX2  ZNF572  PCNXL3  ZZEF1  EDA2R  KCNJ10   P A NX1  PTPMT1  ANLN  UTP20  NOP2  DBH  GRM5  AAK1  NLRP3  SLC16A6  ECE2  CD74  RGS10  LAT  RPL39L  DGKH  TSEN15  ZNF614  KIF9  TMEM86B  HHA T L  MYO3A  VPS13B  NBAS  HDLBP  HPGD  TMEM175  TBC1D10A  MYO19  BBS4  ANKRD12  PRLR  MGA  GDA  SWI5  DLA T  UQCC1  FBXW2  CCDC92  DNAH17  HIP1R  FREM3  SPPL2C  C3orf18  EFCAB12  SSPO  GPR98  CERS2  NTRK1  KAT2A  PLCB3  INPP4B  OR12D2  RDH16  APOB  DOCK5  STAB2  RAPGEF3  CCDC93  IFI16  CLASP1  METTL21A  CAPRIN2  WNK1  SYNE2  MICAL3  ZFR2  GTPBP2  C1orf105  FYCO1  UBR4  KIAA0430  TNRC6B  SLC44A4   TSP A N8  ATP6V1B1  ITGA9  ERBB2  EPPK1  PDE5A  FGFR4  KREMEN1  RRBP1  MEGF8  HOXA7  PLEK2  STAB1  ARAP3  TFPI  ARHGEF15  RASIP1  SLC39A8  SCGB3A1  ABCA1  COBLL1  NPHP3  SLC5A3  ELMOD3  RREB1  ZBTB7B  WBP1L  COL11A1  ACAN  UGGT2  SEMA3D  TBX4  WSCD2  LRRC17  CYTL1  PHTF2  TBX15  MMP14  CDH11  TNC  HSPG2  NID2  ADAM12  FBLN2  LAMA4 Abnormal . PLXND1 encodes a semaphorin class 3 and 4 receptor gene, and therefore, is involved in cell to cell signaling and regulation of growth and development for a number of different cell and tissue types, including those in the cardiovascular system, skeleton, kidneys and the central nervous system [77] [78] [79] [80] [81] . Mutations in this gene are associated with Moebius syndrome [82] [83] [84] [85] and persistent truncus arteriosus 79, 86 . PLXND1 is involved in angiogenesis as part of the SEMA and VEGF signaling pathways [87] [88] [89] [90] . PLXND1 was implicated in the development of type 2 diabetes through its interaction with SEMA3E in mice. SEMA3E and PLXND1 are upregulated in adipose tissue in response to diet-induced obesity, creating a cascade of adipose inflammation, insulin resistance and diabetes mellitus 81 . ACVR1C, also called Activin receptor-like kinase 7 (ALK7), encodes a type I receptor for TGFB (Transforming Growth Factor, Beta-1), and is integral for the activation of SMAD transcription factors; therefore, ACVR1C plays an important role in cellular growth and differentiation [64] [65] [66] [67] [68] , including adipocytes 68 . Mouse Acvr1c decreases secretion of insulin and is involved in lipid storage 69, 72, 73, 91 . ACVR1C exhibits the highest expression in adipose tissue, but is also highly expressed in the brain (GTEx) [69] [70] [71] . Expression is associated with body fat, carbohydrate metabolism and lipids in both obese and lean individuals 70 ). This variant is independent of the previously reported GWAS signal in the RREB1 region (rs1294410; 6:6738752 10 ). The protein encoded by this gene is a zinc finger transcription factor that binds to RAS-responsive elements (RREs) of gene promoters. It has been shown that the calcitonin gene promoter contains an RRE and that the encoded protein binds there and increases expression of calcitonin, which may be involved in Ras/Raf-mediated cell differentiation [97] [98] [99] . The ras-responsive transcription factor RREB1 is a candidate gene for type 2 diabetes associated end-stage kidney disease 98 . This variant is highly intolerant to loss-of function (ExAC constraint score LoF, 1, Supplementary Data 16). DAGLB (7:6449496, rs2303361, novel locus). The minor allele of a common non-synonymous variant (rs2303361, Q664R, MAF 22%) in DAGLB (Diacylglycerol lipase beta) is associated with increased WHRadjBMI (β (s.e.m.) = 0.0136 (0.0025), P value = 6.24 × 10 −8 ). DAGLB encodes a diacylglycerol (DAG) lipase that catalyzes the hydrolysis of DAG to 2-arachidonoyl-glycerol, the most abundant endocannabinoid in tissues. In the brain, DAGL activity is required for axonal growth during development and for retrograde synaptic signaling at mature synapses (2-AG) 100 . The DAGLB variant, rs702485 (7:6449272, r 2 = 0.306 and D' = 1 with rs2303361) has been previously associated with HDL. Pathway analyses indicate a role in the triglyceride lipase activity pathway 101 74, 75 . This gene is possibly involved in the growth hormone signaling pathway and lipid metabolism. The WHRadjBMI-associated of implicated genes and the relatively small number of variants in monogenic disease-causing genes ( Supplementary Fig. 21 ).
Genetic architecture of WHRadjBMI coding variants. We used summary statistics from our stage 1 primary meta-analysis results to estimate the phenotypic variance explained by subsets of variants across various significance thresholds (P < 2 × 10 −7 to 0.2) and conservatively using only independent SNPs (Supplementary Table 7 , Methods and Supplementary Fig. 22 ). For only independent coding variants that reached suggestive significance in stage 1 (P < 2 × 10 −6 ), 33 SNPs explain 0.38% of the variation. The 1,786 independent SNPs with a liberal threshold of P < 0.02 explain 13 times more variation (5.12%), however, these large effect estimates may be subject to winner's curse. When considering all coding variants on the ExomeChip in combined sexes, 46 SNPs with a P < 2 × 10 −6 and 5,917 SNPs with a P < 0.02 explain 0.51 and 13.75% of the variance in WHRadjBMI, respectively. As expected given the design of the ExomeChip, most of the variance explained is attributable to rare and low-frequency coding variants. However, for LF/RVs, those that passed significance in stage 1 explain only 0.10% of the variance in WHRadjBMI. We also estimated variance explained for the same SNPs in women and men separately and observed a greater variance explained in women compared to men (P RsqDiff < 0.002 = 0.05/21, Bonferroni-corrected threshold) at each significance threshold considered (differences ranged from 0.24 to 0.91%).
We conducted penetrance analysis using the UKBB (both sexes combined, and men-and women only) to determine whether there is a significant accumulation of the minor allele in either the centrally obese or non-obese groups (Methods). Three rare variants (MAF ≤1%) with larger effect sizes (effect size >0.90) were included in the penetrance analysis using World Health Organization cutoffs for central obesity. Of these, one SNP (rs55920843-ACVR1C; P sex-combined = 9.25 × 10 −5 ; P women = 4.85 × 10 −5 ) showed a statistically significant difference in the number of carriers and non-carriers of the minor allele in the combined and female-only analysis (sex-combined obese carriers, 2.2%; non-obese carriers, 2.6%; women obese carriers, 2.1%; non-obese women carriers, 2.6%; Supplementary  Table 8 and Supplementary Fig. 23 ).
Drosophila knockdown.
Considering the genetic evidence of adipose and insulin biology in determining body-fat distribution 10 , and the lipid signature of the variants described herein, we examined whole-body triglyceride levels in adult Drosophila, a model organism in which the fat body is an organ functionally analogous to mammalian liver and adipose tissue as triglycerides are the major source of fat storage 45 . Of the 51 genes harboring our 56 significantly associated variants, we identified 27 Drosophila orthologs for functional follow-up analyses. We selected genes with large changes in triglyceride levels (>20% increase or >40% decrease, as chance alone is not a probable cause for changes of this magnitude) from an existing large-scale screen with ≤2 replicates per knockdown strain 45 . Two orthologs, for PLXND1 and DNAH10, met these criteria and were subjected to additional knockdown experiments with ≥5 replicates using tissue-specific drivers (fat body (cg-Gal4) and neuronal (elav-Gal4) specific RNAi-knockdowns) ( Supplementary Table 9 ). A significant (P < 0.025, 0.05/2 orthologs) increase in the total body triglyceride levels was observed in DNAH10 ortholog knockdown strains for both the fat body and neuronal drivers. Only the neuronal driver knockdown for PLXND1 produced a significant change in triglyceride storage. DNAH10 and PLXND1 both lie in previous GWAS-identified regions. Adjacent genes have been highlighted as probable candidates for the DNAH10 association region, including CCDC92 and ZNF664 based on expression quantitative trait locus (eQTL) evidence. Of note, rs11057353 in DNAH10 showed suggestive significance after conditioning on the known GWAS variants in nearby CCDC92 (sex-combined P conditional = 7.56 × 10 −7 ; women-only rs11057353 P conditional = 5.86 × 10 −7 , Supplementary Table 4 ) thus providing some evidence of multiple causal variants/genes underlying this signal. Further analyses are needed to determine whether the implicated coding variants from the current analysis are the putatively functional variants. eQTL lookups. We examined the cis-association of variants with expression level of nearby genes in subcutaneous and visceral omental adipose, skeletal muscle and pancreas tissue from the Genotype-Tissue Expression (GTEx) 46 project, and assessed whether exome and eQTL associations implicated the same signal (Methods and Supplementary Data 14-15 ). The lead exome variant variant rs3812316 in this gene has been associated with the risk of non-alcoholic fatty liver disease and coronary artery disease 74, 102, 103 . Furthermore, Williams-Beuren syndrome (an autosomal dominant disorder characterized by short stature, abnormal weight gain, various cardiovascular defects and mental retardation) is caused by a deletion of about 26 genes from the long arm of chromosome 7 including MLXIPL. MLXIPL is generally intolerant to variation, and therefore conserved (ExAC constraint scores: synonymous = 0.48, missense = 1.16, LoF = 0.68, Supplementary Data 16) . Last, both variants reported here are predicted as possible or probably damaging by one of the algorithms tested (PolyPhen).
RAPGEF3 (12:48143315, rs145878042, novel locus). The major allele of a low-frequency non-synonymous variant in Rap
Guanine-Nucleotide-Exchange Factor (GEF) 3 (rs145878042, L300P, MAF = 1.1%) is associated with increased WHRadjBMI (β (s.e.m) = 0.085 (0.010), P = 7.15 × 10 −17 ). RAPGEF3 codes for an intracellular cAMP sensor, also known as Epac (the Exchange Protein directly Activated by Cyclic AMP). Among its many known functions, RAPGEF3 regulates the ATP sensitivity of the KATP channel involved in insulin secretion 104 , may be important in regulating adipocyte differentiation [105] [106] [107] , plays an important role in regulating adiposity and energy balance 108 . RAPGEF3 is tolerant of mutations (ExAC constraint scores: synonymous, −0.47; non-synonymous, 0.32; LoF, 0 and Supplementary Data 16). Last, our lead variant is predicted as damaging or possibly damaging for all five algorithms examined (SIFT, Polyphen2/ HDIV, Polyphen2/HVAR, LRT, MutationTaster).
TBX15
(1:119427467, rs61730011, known locus). The major allele of a low-frequency non-synonymous variant in T-box 15 (rs61730011, M460R, MAF = 4.3%) is associated with increased WHRadjBMI (β (s.e.m.) = 0.041(0.005)). T-box 15 (TBX15) encodes a developmental transcription factor expressed in adipose tissue, but with higher expression in visceral adipose tissue than in subcutaneous adipose tissue, and is strongly downregulated in overweight and obese individuals 109 . TBX15 negatively controls depot-specific adipocyte differentiation and function 110 and regulates glycolytic myofiber identity and muscle metabolism 111 . TBX15 is moderately intolerant of mutations and therefore conserved (ExAC constraint scores: synonymous, 0.42; nonsynonymous, 0.65; LoF, 0.88 and Supplementary Data 16). Last, our lead variant is predicted as damaging or possibly damaging for four of five algorithms (Polyphen2/HDIV, Polyphen2/HVAR, LRT, MutationTaster).
Box 1 | Genes of biological interest harboring WHR-associated variants (continued)
was associated with expression level of the gene itself for DAGLB, MLXIPL, CCDC92, MAPKBP1, LRRC36 and UQCC1. However, for MLXIPL, MAPKBP1 and LRRC36, the lead variant is also associated with expression of additional nearby genes. At three additional loci, the lead exome variant is only associated with expression level of nearby genes (HEMK1 at C3orf18; NT5DC2, SMIM4 and TMEM110 at STAB1/ITIH3 and C6orf106 at UHRF1BP1). Thus, although detected with a missense variant, these results are also consistent with a regulatory mechanism of effect, and the association signal may well be due to linkage disequilibrium with nearby regulatory variants.
Some of the coding genes implicated by eQTL analyses are known to be involved in adipocyte differentiation or insulin sensitivity: for example, for MLXIPL, the encoded carbohydrate responsive element binding protein is a transcription factor, regulating glucose-mediated induction of de novo lipogenesis in adipose tissue and expression of its beta-isoform in adipose tissue is positively correlated with adipose insulin sensitivity 47, 48 . For CCDC92, the reduced adipocyte lipid accumulation on knockdown confirmed the involvement of its encoded protein in adipose differentiation 49 .
Biological curation. To investigate the possible functional role of the identified variants, we conducted thorough searches of the literature and publicly available bioinformatics databases (Supplementary Data 16-17, Box 1 and Methods). Many of our novel LF/RVs are in genes that are intolerant of non-synonymous mutations (for example, ACVR1C, DARS2, FGFR2; ExAC Constraint Scores >0.5). Other coding variants lie in genes that are involved in glucose homeostasis (for example, ACVR1C, UGGT2, ANGPTL4), angiogenesis (RASIP1), adipogenesis (RAPGEF3) and lipid biology (ANGPTL4, DAGLB).
Discussion
Our analysis of coding variants from ExomeChip data in up to 476,546 individuals identified a total of 56 array-wide significant WHRadjBMI-associated variants in 41 independent association signals, including 24 newly identified (23 novel and one independent of known GWAS signals). Nine of these variants were low-frequency or rare, indicating an important role for such variants in the polygenic architecture of fat distribution. While, due to their rarity, these coding variants explain a small proportion of the trait variance at a population level, they may be more functionally tractable than non-coding variants and have a critical impact at the individual level. For instance, the association between a LF/RV (rs11209026; R381Q; MAF <5% in ExAC) located in the IL23R gene and multiple inflammatory diseases [50] [51] [52] [53] led to development of new therapies targeting IL23 and IL12 in the same pathway [54] [55] [56] . Thus, we are encouraged that our LF/RVs displayed large effect sizes; all but one of the nine novel LF/RVs display larger effects than the 49 SNPs reported in Shungin et al. 10 , and some of these effects were up to seven-fold larger than those previously reported for GWAS. This finding mirrors results for other cardiometabolic traits 57 , and suggests variants of possible clinical significance with even larger effect and rarer variants will probably be detected with greater sample sizes.
We continue to observe sexual dimorphism in the genetic architecture of WHRadjBMI 11 . We identified 19 coding variants with significant sex differences, of which 16 (84%) display larger effects in women compared to men. Of the variants outside GWAS loci, we reported three (two LF/RVs) that show a significantly stronger effect in women and two (one LF/RV) that show a stronger effect in men. Genetic variants continue to explain a higher proportion of the phenotypic variation in body-fat distribution in women compared to men 10, 11 . Of the novel female (DSTYK and ANGPTL4) and male (UGGT2 and MMP14) specific signals, only ANGPTL4 implicated fat distribution related biology associated with both lipid biology and cardiovascular traits (Box 1). Sexual dimorphism in fat distribution is apparent [58] [59] [60] and at sexually dimorphic loci, hormones with different levels in men and women may interact with genomic and epigenomic factors to regulate gene activity, although this remains to be tested. Dissecting the underlying molecular mechanisms of the sexual dimorphism in body-fat distribution and how it is correlated with-and causing-important comorbidities such as cardiometabolic diseases will be crucial for improved understanding of disease pathogenesis.
Overall, we observe fewer significant associations, pathways and cross-trait associations between WHRadjBMI and coding variants on the ExomeChip than Turcot et al. for BMI 25 . One reason for this may be smaller sample size (N WHRadjBMI = 476,546, N BMI = 718,639), and thus, lower statistical power. Power is probably not the only contributing factor, as trait architecture, heritability (possibly overestimated in some phenotypes) and phenotype precision all probably contribute to our study's capacity to identify LF/RVs with large effects. Further, it is possible that the comparative lack of significant findings for WHRadjBMI may be a result of higher selective pressure against genetic predisposition to cardiometabolic phenotypes, thus rarer risk variants 61 . The ExomeChip is limited by the variants present on the chip, which was largely dictated by sequencing studies in European-ancestry populations and MAF detection criteria of ~0.012%. It is probable that through increased sample size, use of chips designed to detect variation across a range of continental ancestries, and high quality, deep imputation with large reference samples, future studies will detect additional variation from the entire allele frequency range that contributes to fat distribution.
The collected genetic and epidemiologic evidence has demonstrated that increased central adiposity is correlated with risk of type 2 diabetes and CVD, and that this association is probably causal with potential mediation through blood pressure, triglyceride-rich lipoproteins, glucose and insulin 9 . This observation yields an immediate follow-up question: which mechanisms regulate depot-specific fat accumulation and are risks for disease driven by increased visceral and/or decreased subcutaneous adipose tissue mass? Pathway analysis identified several novel pathways and gene sets related to metabolism and adipose regulation, bone growth and development and adiponectin, a hormone that has been linked to 'healthy' expansion of adipose tissue and insulin sensitivity 62 . Similarly, expression/ eQTL results support the relevance of adipogenesis, adipocyte biology, and insulin signaling, supporting our previous findings for WHRadjBMI 10 . We also provide evidence suggesting known biological functions and pathways contributing to body-fat distribution (for example, diet-induced obesity, angiogenesis, bone growth/ morphology and lipolysis).
The ultimate aim of genetic investigations of obesity-related traits is to identify dysregulated genomic pathways leading to obesity pathogenesis that may result in a myriad of downstream illnesses. Thus, our findings may enhance the understanding of central obesity and identify new molecular targets to avert its negative health consequences. Significant cross-trait associations are consistent with expected direction of effect for several traits; that is, the WHR-increasing allele is associated with higher values of triglycerides, DBP, fasting insulin, total cholesterol, LDL and type 2 diabetes across many significant variants. However, it is worth noting that there are some exceptions. For example, rs9469913-A in UHRF1BP1 is associated with both increased WHRadjBMI and increased HDL. Also, we identified two variants in MLXIPL (rs3812316 and rs35332062), a well-known lipids-associated locus, in which the WHRadjBMI-increasing allele also increases all lipid levels, risk for hypertriglyceridemia, SBP and DBP. However, our findings show a significant and negative association with HbA1C, and nominally significant and negative associations with two-hour glucose, fasting glucose, and Type 2 diabetes, and potential negative associations with biomarkers for liver disease (for example, gamma glutamyl transpeptidase). Other notable exceptions include ITIH3 (negatively associated with BMI, HbA1C, LDL and SBP), DAGLB (positively associated with HDL), and STAB1 (negatively associated with total cholesterol, LDL and SBP). Therefore, caution in selecting pathways for therapeutic targets is warranted; we must look beyond the effects on central adiposity to the potential cascading effects of related diseases.
A major finding from this study is the importance of lipid metabolism for body-fat distribution. In fact, pathway analyses that highlight enhanced lipolysis, cross-trait associations with circulating lipid levels, existing biological evidence from the literature, and knockdown experiments in Drosophila, point to novel candidate genes (ANGPTL4, ACVR1C, DAGLB, MGA, RASIP1 and IZUMO1) and new candidates in known regions (DNAH10 10 and MLXIPL 14 ) related to lipid biology and their role in fat storage. ACVR1C, MLXIPL and ANGPTL4, all of which are involved in lipid homeostasis, all are excellent candidate genes for central adiposity. Carriers of inactivating mutations in ANGPTL4 (Angiopoietin Like 4), for example, display low triglycerides and low risk of coronary artery disease 63 . ACVR1C encodes the activin receptor-like kinase 7 protein (ALK7), a receptor for the transcription factor TGFB-1, well-known for its central role in general growth and development [64] [65] [66] [67] [68] and adipocyte development in particular 68 . ACVR1C exhibits the highest expression in adipose tissue, but is also highly expressed in the brain [69] [70] [71] . In mice, decreased activity of ACVR1C upregulates PPARγ and C/EBPα pathways and increases lipolysis in adipocytes, thus decreasing weight and diabetes 69, 72, 73 . Such activity suggests a role for ALK7 in adipose tissue signaling and a possible therapeutic target. MLXIPL, also important for lipid metabolism and postnatal cellular growth, encodes a transcription factor that activates triglyceride synthesis genes in a glucose-dependent manner 74, 75 . The lead exome variant in MLXIPL is highly conserved, most probably damaging and associated with reduced MLXIPL expression in adipose tissue. Furthermore, in a recent longitudinal, in vitro transcriptome analysis of adipogenesis in human adiposederived stromal cells, gene expression of MLXIPL was upregulated during the maturation of adipocytes, suggesting a critical role in the regulation of adipocyte size and accumulation 76 . However, given our cross-trait associations with variants in MLXIPL and diabetes-related traits, development of therapeutic targets must be approached cautiously.
Our 24 novel variants for WHRadjBMI highlight the importance of lipid metabolism in the genetic underpinnings of body-fat distribution. We continue to demonstrate the critical role of adipocyte biology and insulin resistance for central obesity and offer support for potentially causal genes underlying previously identified fat distribution loci. Notably, our findings offer potential new therapeutic targets for intervention in the risks associated with abdominal fat accumulation and represents a major advance in our understanding of the underlying biology and genetic architecture of central adiposity. 
URLs

Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41588-018-0334-2. Supplementary Data 1-3) . Informed consent was obtained by the parent study and protocols approved by each study's institutional review boards.
Phenotypes. For each study, WHR (waist circumference divided by hip circumference) was corrected for age, BMI and genomic principal components (derived from GWAS data, the variants with MAF >1% on the ExomeChip, and ancestry informative markers available on the ExomeChip), as well as any additional study-specific covariates (for example, recruiting center), in a linear regression model. For studies with unrelated individuals, residuals were calculated separately by sex, whereas for family based studies sex was included as a covariate in models with both men and women. Residuals for case/control studies were calculated separately. Finally, residuals were inverse normal transformed and used as the outcome in association analyses. Phenotype descriptives by study are shown in Supplementary Data 3.
Genotypes and quality control. Most studies followed a standardized protocol and performed genotype calling using the algorithms indicated in Supplementary Data 2, which typically included zCall 3 . For 10 studies from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, raw intensity data for samples from seven genotyping centers were combined for joint calling 4 . Study-specific quality control of the genotyped variants was implemented before association analysis ( Supplementary Data 1,2) . To assess whether any significant associations with rare and low-frequency variants could be due to allele calling in smaller studies, we performed a sensitivity meta-analysis of all large studies (>5,000 participants) compared to all studies. We found very high concordance for effect sizes, suggesting that smaller studies do not bias our results ( Supplementary  Fig. 24 ).
Study-level statistical analyses.
Each cohort performed single-variant analyses for both additive and recessive models in each ancestry, for sexes combined and sex-specific groups, with either RAREMETALWORKER (see URLs) or RVTESTs (see URLs). to associate inverse normal transformed WHRadjBMI with genotype accounting for cryptic relatedness (kinship matrix) in a linear mixed model. Both programs perform score-statistic rare-variant association analysis, accommodate unrelated and related individuals and provide single-variant results and variancecovariance matrices. The covariance matrix captures linkage disequilibrium between markers within 1 Mb, which is used for gene-level meta-analyses and conditional analyses 113, 114 .
Centralized quality control. Individual cohorts identified ancestry outliers based on 1000 Genomes Phase 1 reference populations. A centralized quality control procedure implemented in EasyQC 115 was applied to individual cohort summary statistics to identify cohort-specific problems: (1) possible errors in phenotype residual transformation; (2) strand issues and (3) inflation due to population stratification, cryptic relatedness and genotype biases.
Meta-analyses.
Meta-analyses were carried out in parallel by two analysts at two sites using RAREMETAL 113 . We excluded variants if they had call rate <95%, Hardy-Weinberg equilibrium P < 1 × 10 −7 , or large allele frequency deviations from reference populations (>0.6 for all ancestries analyses and >0.3 for ancestryspecific population analyses). We also excluded markers not present on the Illumina ExomeChip array 1.0, Y-chromosome and mitochondrial variants, indels, multiallelic markers and problematic variants on the basis of Blat-based sequence alignment. Significance for single-variant analyses was defined at an array-wide level (P < 2 × 10 −7 ). For all suggestive significant variants (P < 2 × 10 −6 ) from stage 1, we calculated P sexhet for each SNP, testing for differences between women-specific and men-specific beta estimates and standard errors using EasyStrata 116 . Each SNP that reached P sexhet < 0.05 per number of variants tested (70 variants brought forward from stage 1, P sexhet < 7.14 × 10 −4 ) was considered significant. Additionally, while each individual study was asked to perform association analyses stratified by ancestry and adjusted for population stratification, all study-specific summary statistics were combined in our all ancestry meta-analyses. To investigate potential heterogeneity across ancestries, we examined ancestry-specific meta-analysis results for our top 70 variants from stage 1 and found no evidence of significant across-ancestry heterogeneity for any of our top variants (I 2 values noted in Supplementary Data 4-6) .
For the gene-based analyses, we applied two sets of criteria to select variants with a MAF <5% in each ancestry based on coding variant annotation from five prediction algorithms (PolyPhen2, HumDiv and HumVar, LRT, MutationTaster and SIFT) 117 . Our broad gene-based tests included nonsense, stop-loss, splice site and missense variants annotated as damaging by at least one algorithm mentioned above. Our strict gene-based tests included only nonsense, stop-loss, splice site and missense variants annotated as damaging by all five algorithms. These analyses were performed using the sequence kernel association test (SKAT) and variable threshold methods in RAREMETAL 113 . Statistical significance for gene-based tests was set at a Bonferroni-corrected threshold of P < 2.5 × 10 −6 (0.05/~20,000 genes).
Genomic inflation.
We observed marked genomic inflation of the test statistics even after controlling for population stratification arising mainly from common markers; λ GC in the primary meta-analysis (combined ancestries and combined sexes) was 1.06 for all variants and 1.37 for common coding and splice site markers, respectively ( Supplementary Figs. 3, 7 and 13 and Supplementary Table  10 ). Such inflation is expected for a highly polygenic trait such as WHRadjBMI, for studies using a non-random set of variants across the genome, and is consistent with our very large sample size 115, 118, 119 .
Conditional analyses. The RAREMETAL R-package 113 was used to identify independent WHRadjBMI association signals across all ancestries and European meta-analysis results. RAREMETAL performs conditional analyses using covariance matrices to distinguish true signals from shadows of adjacent significant variants in linkage disequilibrium. First, we identified lead variants (P < 2 × 10 −7 ) based on a 1 Mb window centered on the most significant variant. We then conditioned on the lead variants in RAREMETAL and kept new lead signals at P < 2 × 10 −7 for conditioning in a second round of analysis. The process was repeated until no additional signal emerged below the pre-specified P value threshold (P < 2 × 10 −7 ).
To test if the associations detected were independent of previously published WHRadjBMI variants 10, 14, 16 , we used RAREMETAL to perform conditional analyses in the stage 1 discovery set if the GWAS variant or its proxy (r 2 ≥ 0.8) was on the ExomeChip. All variants identified in our meta-analysis and the previously published variants were available in the UKBB dataset 112 , which was used as a replacement dataset if a good proxy was not on the ExomeChip. All conditional analyses in the UKBB were performed using SNPTEST [120] [121] [122] .
The conditional analyses were carried out reciprocally, conditioning on the ExomeChip variant and then the previously published variant. An association was considered independent if it was significant before conditional analysis (P < 2 × 10 −7 ) with both the exome chip variant and the previously published variant, and the observed association with our variant remained significant on conditional analysis. Conditional P values between 9 × 10 −6 and 0.05 were considered inconclusive, while those <9 × 10 −6 were considered suggestive.
Stage 2 meta-analyses. In stage 2, we sought to validate 70 stage 1 variants (P < 2 × 10 −6 ) in two independent studies, UKBB (N = 119,572) and deCODE (N = 12,605), using the same quality control and analytical methodology. Genotyping, study descriptions and phenotype descriptives are provided in Supplementary Data 1-3. Stage 1 and 2 meta-analysis was performed using the inverse-variance weighted fixed-effects method. Significant associations were defined as those nominally significant (P < 0.05) in stage 2 when available in stage 2, and array-wide significance for stage 1 and 2 at P < 2 × 10 −7 (0.05/~250,000 246,328 variants tested). Variants are considered novel and statistically significant if they were greater than 1 Mb from a previously identified WHRadjBMI lead SNP [10] [11] [12] [13] [14] [15] [16] and achieved a significance threshold of P < 2 × 10 −7 .
Pathway enrichment analyses: EC-DEPICT. We adapted DEPICT, a gene set enrichment analysis method for GWAS data, for use with the ExomeChip ('EC-DEPICT') described further in a companion manuscript 21 . DEPICT uses 'reconstituted' gene sets, where different types of gene set (for example, canonical pathways, protein-protein interaction networks, and mouse phenotypes) were extended through large-scale microarray data (see Pers et al. 20 for details). EC-DEPICT computes P values based on Swedish ExomeChip data (Malmö Diet and Cancer (MDC), All New Diabetics in Scania (ANDIS) and Scania Diabetes Registry (SDR) cohorts, N = 11,899) and, unlike DEPICT, takes as input only genes directly containing substantial (coding) variants rather than all genes in a specified linkage disequilibrium (Supplementary Note).
Two analyses were performed for WHRadjBMI ExomeChip: one with all variants P < 5 × 10 −4 (49 significant gene sets in 25 meta-gene sets, FDR < 0.05) and one with all variants >1 Mb from known GWAS loci 10 (26 significant gene sets in 13 meta-gene sets, FDR < 0.05). Affinity propagation clustering 123 was used to group highly correlated gene sets into 'meta-gene sets'; for each meta-gene set, the member gene set with the best P value was used for visualization (Supplementary Note). EC-DEPICT was written in Python (see URLs).
Pathway enrichment analyses: PASCAL. We also applied PASCAL pathway analysis 22 to summary statistics from stage 1 for all coding variants. PASCAL derives gene-based scores (SUM and MAX) and tests for over-representation of high gene scores in predefined biological pathways. We performed both MAX and SUM estimations for pathway enrichment. MAX is sensitive to gene sets driven by a single signal, while SUM is better for multiple variant associations in the same gene. We used standard pathway libraries from KEGG, REACTOME and BIOCARTA, and also added dichotomized (z > 3) reconstituted gene sets from DEPICT 20 . To accurately estimate SNP-by-SNP correlations even for rare variants, we used the UK10K data (TwinsUK 124 and ALSPAC 125 , N = 3781). To distinguish contributions of regulatory and coding variants, we also applied PASCAL to summary statistics of only regulatory variants (20 kb upstream) and regulatory+coding variants from the Shungin et al. 10 study. In this way, we could investigate what is gained by analyzing coding variants.
Monogenic obesity enrichment analyses. We compiled two lists consisting of 31 genes with strong evidence that disruption causes monogenic forms of insulin resistance or diabetes, and eight genes with evidence that disruption causes monogenic forms of lipodystrophy. To test for association enrichment, we conducted simulations by matching each gene with others based on gene length and number of variants tested to create 1,000 matched gene sets and assessed how often the number of variants exceeding set significance thresholds was greater than in our monogenic obesity gene set.
Variance explained. We estimated phenotypic variance explained by stage 1 associations in all ancestries for men, women, and combined sexes 126 . For each associated region, we pruned subsets of SNPs within 500 kb of SNPs with the lowest P value and used varying P value thresholds (ranging from 2 × 10 −7 to 0.02) from the combined sexes results. Additionally, we examined all variants and independent variants across a range of MAFs. The variance explained by each subset of SNPs in each stratum was estimated by summing the variance explained by individual top coding variants. To compare variance explained between men and women, we tested for significant differences assuming the weighted sum of χ 2distributed variables tend to a Gaussian distribution following Lyapunov's central limit theorem 126, 127 .
Cross-trait lookups. To evaluate relationships between WHRadjBMI and related cardiometabolic, anthropometric, and reproductive traits, association results for the 51 WHRadjBMI coding SNPs were requested from seven consortia, including ExomeChip data from GIANT (BMI, height), Global Lipids Genetics Consortium (GLGC) (total cholesterol, triglycerides, HDL-cholesterol, LDLcholesterol), International Consortium for Blood Pressure (IBPC) 128 (systolic and diastolic blood pressure), Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) (glycemic traits) and DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) consortium (type 2 diabetes)) 21, [25] [26] [27] [28] [29] . For coronary artery disease, we accessed 1000 Genomes Project-imputed GWAS data released by CARDIoGRAMplusC4D 129 and for age at menarche and menopause, we used a combination of ExomeChip and 1000 Genomes Project-imputed GWAS data from ReproGen. Heat maps were generated with gplots (R v.3.3.2) using Euclidean distance based on P value, and direction of effect and complete linkage clustering (see URLs).
GWAS catalog lookups.
To determine whether substantial coding variants were associated with any related cardiometabolic or anthropometric traits, we also searched the NHGRI-EBI GWAS Catalog for previous associations near our lead SNPs (+/-500 kb). We used PLINK to calculate linkage disequilibrium using ARIC European participants. All GWAS Catalog SNPs in the specified regions with an r 2 > 0.7 were evaluated 37 . Consistent direction of effect was based on the WHRadjBMI-increasing allele, linkage disequilibrium and allele frequency. We do not comment on direction of effect when a GWAS Catalog variant was not identical or in high linkage disequilibrium (r 2 > 0.9) with the WHR variant and MAF >45%.
Body-fat percentage associations. We performed body-fat percentage and truncal fat percentage lookups of 48 of the 56 WHRadjBMI identified variants (Tables 1 and 2) available in UKBB. GWAS for body-fat percentage and truncal fat percentage in UKBB excluded pregnant or possibly pregnant women, individuals with BMI <15, or those without genetically confirmed European ancestry, resulting in a sample size of 120,286. Estimated body-fat percentage and truncal fat percentage were obtained using the Tanita BC418MA body composition analyzer (Tanita). Participants were non-fasting and did not follow any specific instructions before bioimpedance measurements. SNPTEST was used to perform the analyses based on residuals adjusted for age, 15 principal components, assessment center and the genotyping chip 120 .
Collider bias. To evaluate SNPs for possible collider bias 17 , we used results from a recent GIANT BMI GWAS 25 . For each significant SNP from our additive models, WHRadjBMI associations were corrected for potential bias due to associations between each variant and BMI (Supplementary Note). Variants meeting Bonferroni-corrected significance (P corrected < 9.09 × 10 −4 , 0.05/55 variants examined) were considered robust against collider bias.
Drosophila RNAi-knockdown experiments. For each gene with WHRadjBMIassociated coding variants in the final combined meta-analysis (P < 2 × 10 −7 ), its corresponding Drosophila orthologs were identified in the Ensembl ortholog database (see URLs), when available. Drosophila triglyceride content values were mined from a publicly available genome-wide fat screen dataset 45 to identify potential genes for follow-up knockdowns. Estimated values represent fractional changes in triglyceride content in adult male flies. Data are from male progeny of crosses between male UAS-RNAi flies from the Vienna Drosophila Resource Center and Hsp70-GAL4; Tub-GAL8ts virgin females. (Supplementary Note). The screen comprised one to three biological replicates. We followed up each gene with a >0.2 increase or >0.4 decrease in triglyceride content.
Orthologs for two genes were brought forward for follow-up, DNAH10 and PLXND1. For both genes, we generated adipose tissue (cg-Gal4) and neuronal (elav-Gal4) specific RNAi-knockdown crosses to knockdown transcripts in a tissue-specific manner, leveraging upstream activation sequence (UAS)-inducible short-hairpin knockdown lines, available through the Vienna Drosophila Resource Center. Specifically, elav-Gal4, which drives expression of the RNAi construct in post mitotic neurons starting at embryonic stages all the way to adulthood, was used. Cg drives expression in the fat body and hemocytes starting at embryonic stage 12, all the way to adulthood. (Supplementary Note). Resulting triglyceride values were normalized to fly weight and larval/population density. We used the non-parametric Kruskall-Wallis test to compare wild type with knockdown lines. eQTLs analysis. We queried the significant variant (Exome coding SNPs)-gene pairs associated with eGenes across five metabolically relevant tissues (skeletal muscle, subcutaneous adipose, visceral adipose, liver and pancreas) with at least 70 samples in the GTEx database 46 . For each tissue, variants were selected based on the following thresholds: the minor allele was observed in at least 10 samples and MAF ≥1%. eGenes, genes with a significant eQTL, are defined on a FDR 130 threshold of ≤0.05 of beta distribution-adjusted empirical P value from FastQTL. Nominal P values were generated for each variant-gene pair by testing the alternative hypothesis that the slope of a linear regression model between genotype and expression deviates from zero. To identify all significant variant-gene pairs associated with eGenes, a genome-wide empirical P value threshold 64 (pt) was defined as the empirical P value of the gene closest to the 0.05 FDR threshold. pt was then used to calculate a nominal P value threshold for each gene based on the beta distribution model (from FastQTL) of the minimum P value distribution f(pmin) obtained from the permutations for the gene. For each gene, variants with a nominal P value below the gene-level threshold were considered significant and included in the final list of variant-gene pairs 64 . For each eGene, we also listed the most significantly associated variants (eSNP). Only these exome SNPs with r 2 > 0.8 with eSNPs were considered for biological interpretation (supplementary eQTL GTEx).
We also performed cis-eQTL analysis in 770 METSIM subcutaneous adipose tissue samples as described in Civelek et al. 131 . A FDR was calculated using all P values from the cis-eQTL detection in the q-value package in R. Variants associated with nearby genes at an FDR of less than 1% were considered to be significant (equivalent P < 2.46 × 10 −4 ).
For loci with more than one microarray probeset of the same gene associated with the exome variant, we selected the probeset that provided the strongest linkage disequilibrium r 2 between the exome variant and the eSNP. In reciprocal conditional analysis, we conditioned on the lead exome variant by including it as a covariate in the cis-eQTL detection and reporting the P value of the eSNP and vice versa. Signals were considered coincident if both the lead exome variant and the eSNP were no longer significant after conditioning on the other and the variants were in high linkage disequilibrium (r 2 > 0.80).
For loci that also harbored reported GWAS variants, we performed reciprocal conditional analysis between the GWAS lead variant and the lead eSNP. For loci with more than one reported GWAS variant, the GWAS variant with the strongest linkage disequilibrium I 2 with the lead eSNP was reported.
Penetrance analysis. Phenotype and genotype data from UKBB were used for penetrance analysis. Three of 16 rare and low-frequency variants (MAF ≤1%) detected in the final stage 1 and 2 meta-analysis were available in UKBB and had relatively larger effect sizes (>0.90). Phenotype data for these three variants were stratified by WHR using World Health Organization (WHO) guidelines, which consider women and men with WHR greater than 0.85 and 0.90 as obese, respectively. Genotype and allele counts were used to calculate the number of carriers of the minor allele. The number of obese versus non-obese carriers for women, men and sexes combined was compared using a χ 2 test. Significance was determined using a Bonferroni correction for the number of tests performed (0.05/9 = 5.5 × 10 −3 ). 
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